IP Library Granted Patent US 12661362
Granted Patent B2
US 12661362 · App. 18/081,951 · Granted Jun 23, 2026

Methods for the prevention and treatment of hearing loss

Inventors: Jian Zuo (Carlsbad, CA); Pezhman Salehi Dermanaki (Elkhorn, NE); Marisa Laura Zallocchi (Omaha, NE); Sarath Vijayakumar (Omaha, NE)
Assignee: Ting Therapeutics, Inc.
A61K31/5377A61F11/00A61K31/122A61K31/165A61K31/167A61K31/397A61K31/506A61K31/513A61K31/517A61K31/609A61K31/7036A61K33/243A61K45/06A61P27/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12661362
App. No.
18/081,951
Granted
Jun 23, 2026
Kind
B2
Abstract

Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and Cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of Cisplatin- or noise-induced hearing loss. In one aspect, use of Niclosamide, Ingenol, and Elesclomol as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims (1)

1 . A method to prevent ear hair cell loss caused by a chemotherapeutic agent comprising: administering to a mammal in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is Niclosamide, or a pharmaceutically acceptable salt thereof to prevent ear hair cell loss caused by the administration of the chemotherapeutic agent, wherein the chemotherapeutic agent is Cisplatin.